Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative chemotherapy with or without PD-1 inhibitor for locally advanced gastro-esophageal junction adenocarcinoma
ChiCTR2400081098Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, capecitabine and tegafur in gastroesophageal junction adenocarcinoma (3 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Tumor regression grade 0/1 rate and Completeness of perioperative treatment. Started Feb 2024; status: recruiting.
02
Drugs
oxaliplatincapecitabinetegafur
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400081098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081098.